Role of chitinase-like proteins in cancer

Biological Chemistry

Volumn 397, Issue 3, 2016, Pages 231-247

  Kzhyshkowska, Julia ^a,b,c   Yin, Shuiping ^a   Liu, Tengfei ^a   Riabov, Vladimir ^a,b   Mitrofanova, Irina ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TOMSK STATE UNIVERSITY   (Russian Federation)

^c German Red Cross Blood Donation Service Baden Württemberg Hessen   (Germany)

Author keywords

angiogenesis; lectin; metastasis; SI CLP; YKL 39; YKL 40

Indexed keywords

ANTIBODY; CHITINASE; CHITINASE LIKE PROTEIN; RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; YKL 39 PROTEIN; YKL 40 PROTEIN; ADIPOCYTOKINE; CARRIER PROTEIN; CHI3L1 PROTEIN, HUMAN; CHI3L2 PROTEIN, HUMAN; CHID1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1; LECTIN;

ANGIOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELLS BY BODY ANATOMY; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; TUMOR CELL; TUMOR GROWTH; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ADIPOKINES; AMINO ACID SEQUENCE; ANIMALS; CARRIER PROTEINS; CHITINASE-3-LIKE PROTEIN 1; CHITINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; LECTINS; NEOPLASMS;

EID: 84958811463     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2015-0269     Document Type: Review

References (133)

1. Akiyama, Y., Ashizawa, T., Komiyama, M., Miyata, H., Oshita, C., Omiya, M., Iizuka, A., Kume, A., Sugino, T., Hayashi, N., et al. (2014). YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. Oncol. Rep. 32, 159-166.
2. Areshkov, P.A., Kavsan, V.M. (2010). Chitinase 3-like protein 2 (CHI3L2, YKL-39) activates phosphorylation of extracellular signal-regulated kinases ERK1/ERK2 in human embryonic kidney (HEK293) and human glioblastoma (U87 MG) cells. Tsitol. Genet. 44, 3-9.
3. Areshkov, P.O., Avdieiev, S.S., Balynska, O.V., Leroith, D., Kavsan, V.M. (2012). Two closely related human members of chitinase-like family, CHI3L1 and CHI3L2, activate ERK1/2 in 293 and U373 cells but have the different influence on cell proliferation. Int. J. Biol. Sci. 8, 39-48.
4. Balkwill, F.R., Capasso, M., Hagemann, T. (2012). The tumor microenvironment at a glance. J. Cell Sci. 125, 5591-5596.
5. Barbouri, D., Afratis, N., Gialeli, C., Vynios, D.H., Theocharis, A.D., Karamanos, N.K. (2014). Syndecans as modulators and potential pharmacological targets in cancer progression. Front Oncol. 4, 4.
6. Barderas, R., Bartolome, R.A., Fernandez-Acenero, M.J., Torres, S., Casal, J.I. (2012). High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res. 72, 2780-2790.
7. Bernardi, D., Podswiadek, M., Zaninotto, M., Punzi, L., Plebani, M. (2003). YKL-40 as a marker of joint involvement in inflammatory bowel disease. Clin. Chem. 49, 1685-1688.
8. Bhardwaj, R., Yester, J.W., Singh, S.K., Biswas, D.D., Surace, M.J., Waters, M.R., Hauser, K.F., Yao, Z., Boyce, B.F., Kordula, T. (2015). RelB/p50 complexes regulate cytokine-induced YKL-40 expression. J. Immunol. 194, 2862-2870.
9. Bigg, H.F., Wait, R., Rowan, A.D., Cawston, T.E. (2006). The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J. Biol. Chem. 281, 21082-21095.
10. Biggar, R.J., Johansen, J.S., Smedby, K.E., Rostgaard, K., Chang, E.T., Adami, H.O., Glimelius, B., Molin, D., Hamilton-Dutoit, S., Melbye, M. et al. (2008). Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin. Cancer Res. 14, 6974-6978.
11. Bonneh-Barkay, D., Bissel, S.J., Kofler, J., Starkey, A., Wang, G., Wiley, C.A. (2012). Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 22, 530-546.
12. Boot, R.G., Blommaart, E.F., Swart, E., Ghauharali-van der Vlugt, K., Bijl, N., Moe, C., Place, A., Aerts, J.M. (2001). Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J. Biol. Chem. 276, 6770-6778.
13. Brocheriou, I., Maouche, S., Durand, H., Braunersreuther, V., Le Naour, G., Gratchev, A., Koskas, F., Mach, F., Kzhyshkowska, J., Ninio, E. (2011). Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis 214, 316-324.
14. Chang, N.C., Hung, S.I., Hwa, K.Y., Kato, I., Chen, J.E., Liu, C.H., Chang, A.C. (2001). A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J. Biol. Chem. 276, 17497-17506.
15. Chen, C.C., Pekow, J., Llado, V., Kanneganti, M., Lau, C.W., Mizoguchi, A., Mino-Kenudson, M., Bissonnette, M., Mizoguchi, E. (2011). Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitisassociated neoplasia. Am. J. Pathol. 179, 1494-1503.
16. Chudecka-Glaz, A., Gorski, B., Zielinska, D., Blogowski, W., Wojciechowska, I., Bedner, R., Rzepka-Gorska, I. (2009). Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation-comparison to CA 125 antigen. Eur. J. Gynaecol. Oncol. 30, 668-671.
17. Cintin, C., Johansen, J.S., Christensen, I.J., Price, P.A., Sorensen, S., Nielsen, H.J. (1999). Serum YKL-40 and colorectal cancer. Br. J. Cancer 79, 1494-1499.
18. Colton, C.A., Mott, R.T., Sharpe, H., Xu, Q., Van Nostrand, W.E., Vitek, M.P. (2006). Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation 3, 27.
19. Cuddapah, V.A., Robel, S., Watkins, S., Sontheimer, H. (2014). A neurocentric perspective on glioma invasion. Nat. Rev. Neurosci. 15, 455-465.
20. Di Rosa, M., Tibullo, D., Malaguarnera, M., Tuttobene, M., Malaguarnera, L. (2013). Comparison of YKL-39 and CHIT-1 expression during macrophages differentiation and polarization. Modern Research in Inflammation 2, 82-89.
21. Diaz-Lagares, A., Alegre, E., Arroyo, A., Gonzalez-Cao, M., Zudaire, M.E., Viteri, S., Martin-Algarra, S., Gonzalez, A. (2011). Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 32, 1155-1161.
22. Diefenbach, C.S., Shah, Z., Iasonos, A., Barakat, R.R., Levine, D.A., Aghajanian, C., Sabbatini, P., Hensley, M.L., Konner, J., Tew, W., et al. (2007). Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol. Oncol. 104, 435-442.
23. Egberts, F., Kotthoff, E.M., Gerdes, S., Egberts, J.H., Weichenthal, M., Hauschild, A. (2012). Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur. J. Cancer 48, 695-702.
24. Egeblad, M., Nakasone, E.S., Werb, Z. (2010). Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 18, 884-901.
25. Elias, J.A., Homer, R.J., Hamid, Q., Lee, C.G. (2005). Chitinases and chitinase-like proteins in T H 2 inflammation and asthma. J. Allergy Clin. Immunol. 116, 497-500.
26. Erzin, Y., Uzun, H., Karatas, A., Celik, A.F. (2008). Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease. J. Gastroenterol. Hepatol. 23, e357-362.
27. Faibish, M., Francescone, R., Bentley, B., Yan, W., Shao, R. (2011). A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol. Cancer Ther. 10, 742-751.
28. Feodorova, Y., Tashkova, D., Simitchiev, K., Todorov, A., Kostov, G., Dimov, R., Sarafian, V. (2015). Dependence of YKL-40 mRNA tissue levels on KRAS mutation status in colorectal cancer. IJSM 1, 48-52.
29. Francescone, R.A., Scully, S., Faibish, M., Taylor, S.L., Oh, D., Moral, L., Yan, W., Bentley, B., Shao, R. (2011). Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 286, 15332-15343.
30. Francescone, R., Ngernyuang, N., Yan, W., Bentley, B., Shao, R. (2014). Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis. Oncogene 33, 2110-2122.
31. Fujisawa, T., Joshi, B.H., Puri, R.K. (2012). IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int. J. Cancer 131, 344-356.
32. Fusetti, F., Pijning, T., Kalk, K.H., Bos, E., Dijkstra, B.W. (2003). Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J. Biol. Chem. 278, 37753-37760.
33. Gara, S.K., Wang, Y., Patel, D., Liu-Chittenden, Y., Jain, M., Boufraqech, M., Zhang, L., Meltzer, P. S., Kebebew, E. (2015). Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. Nuc. Acids Res. 43, 9327-9339.
34. Goerdt, S., Walsh, L.J., Murphy, G.F., Pober, J.S. (1991). Identification of a novel high molecular weight protein preferentially expressed by sinusoidal endothelial cells in normal human tissues. J. Cell Biol. 113, 1425-1437.
35. Golestaneh, N., Mishra, B. (2005). TGF-, neuronal stem cells and glioblastoma. Oncogene 24, 5722-5730.
36. Gratchev, A., Schmuttermaier, C., Mamidi, S., Gooi, L., Goerdt, S., Kzhyshkowska, J. (2008). Expression of osteoarthritis marker YKL-39 is stimulated by transforming growth factor b (TGF-b) and IL-4 in differentiating macrophages. Biomark. Insights 3, 39-44.
37. Hakala, B.E., White, C., Recklies, A.D. (1993). Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J. Biol. Chem. 268, 25803-25810.
38. He, C.H., Lee, C.G., Dela Cruz, C.S., Lee, C.M., Zhou, Y., Ahangari, F., Ma, B., Herzog, E.L., Rosenberg, S.A., Li, Y., et al. (2013). Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor a2. Cell Rep. 4, 830-841.
39. Henrissat, B., Davies, G. (1997). Structural and sequence-based classification of glycoside hydrolases. Curr. Opin. Struct. Biol. 7, 637-644.
40. Hogdall, E.V., Ringsholt, M., Hogdall, C.K., Christensen, I.J., Johansen, J.S., Kjaer, S.K., Blaakaer, J., Ostenfeld-Moller, L., Price, P.A., Christensen, L.H. (2009). YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 9, 8.
41. Hollak, C.E., van Weely, S., van Oers, M.H., Aerts, J.M. (1994). Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 93, 1288-1292.
42. Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K.S., Edgar, M.A., Tanwar, M.K., Rao, J.S., Fleisher, M., DeAngelis, L.M., Holland, E.C. (2006). YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer. Res. 12, 5698-5704.
43. Hu, B., Trinh, K., Figueira, W.F., Price, P.A. (1996). Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J. Biol. Chem. 271, 19415-19420.
44. Iwamoto, F.M., Hormigo, A. (2014). Unveiling YKL-40, from serum marker to target therapy in glioblastoma. Front Oncol. 4, 90.
45. Iwamoto, F.M., Hottinger, A.F., Karimi, S., Riedel, E., Dantis, J., Jahdi, M., Panageas, K.S., Lassman, A.B., Abrey, L.E., Fleisher, M., et al. (2011). Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro. Oncol. 13, 1244-1251.
46. Jensen, B.V., Johansen, J.S., Price, P.A. (2003). High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer. Res. 9, 4423-4434.
47. Jin, H.M., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Kirkpatrick, R.B., Rosenberg, M. (1998). Genetic characterization of the murine Ym1 gene and identification of a cluster of highly homologous genes. Genomics 54, 316-322.
48. Johansen, J.S., Williamson, M.K., Rice, J.S., Price, P.A. (1992). Identification of proteins secreted by human osteoblastic cells in culture. J. Bone Miner. Res. 7, 501-512.
49. Johansen, J.S., Christensen, I.J., Riisbro, R., Greenall, M., Han, C., Price, P.A., Smith, K., Brunner, N., Harris, A.L. (2003). High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res. Treat. 80, 15-21.
50. Johansen, J.S., Milman, N., Hansen, M., Garbarsch, C., Price, P.A., Graudal, N. (2005). Increased serum YKL-40 in patients with pulmonary sarcoidosis-a potential marker of disease activity Respir. Med. 99, 396-402.
51. Johansen, J.S., Brasso, K., Iversen, P., Teisner, B., Garnero, P., Price, P.A., Christensen, I.J. (2007). Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin. Cancer Res. 13, 3244-3249.
52. Johansen, J.S., Schultz, N.A., Jensen, B.V. (2009). Plasma YKL-40: a potential new cancer biomarker Future Oncol. 5, 1065-1082.
53. Johansen, J.S., Bojesen, S.E., Tybjaerg-Hansen, A., Mylin, A.K., Price, P.A., Nordestgaard, B.G. (2010). Plasma YKL-40 and total and disease-specific mortality in the general population. Clin. Chem. 56, 1580-1591.
54. Johansen, J.S., Christensen, I.J., Jorgensen, L.N., Olsen, J., Rahr, H.B., Nielsen, K.T., Laurberg, S., Brunner, N., Nielsen, H. J. (2015). Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 24, 621-626.
55. Joshi, A., Cao, D. (2009). TGF-b signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci. (Landmark edition) 15, 180-194.
56. Junker, N., Johansen, J.S., Andersen, C.B., Kristjansen, P.E. (2005). Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 48, 223-231.
57. Kang, E.J., Jung, H., Woo, O.H., Park, K.H., Woo, S.U., Yang, D.S., Kim, A.R., Lee, J.B., Kim, Y.H., Kim, J.S., et al. (2014). YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol. 35, 277-286.
58. Karikoski, M., Marttila-Ichihara, F., Elima, K., Rantakari, P., Hollmen, M., Kelkka, T., Gerke, H., Huovinen, V., Irjala, H., Holmdahl, R., et al. (2014). Clever-1/stabilin-1 controls cancer growth and metastasis. Clin. Cancer Res. 20, 6452-6464.
59. Kavsan, V., Dmitrenko, V., Boyko, O., Filonenko, V., Avdeev, S., Areshkov, P., Marusyk, A., Malisheva, T., Rozumenko, V., Zozulya, Y. (2008). Overexpression of YKL-39 gene in glial brain tumors. Scholarly Research Exchange 2008.
60. Kawada, M., Seno, H., Kanda, K., Nakanishi, Y., Akitake, R., Komekado, H., Kawada, K., Sakai, Y., Mizoguchi, E., Chiba, T. (2012). Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 31, 3111-3123.
61. Kjaergaard, A.D., Bojesen, S.E., Johansen, J.S., Nordestgaard, B.G. (2010). Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann. Neurol. 68, 672-680.
62. Kjaergaard, A.D., Nordestgaard, B.G., Johansen, J.S., Bojesen, S.E. (2015). Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int. J. Cancer 137, 2696-2704.
63. Knorr, T., Obermayr, F., Bartnik, E., Zien, A., Aigner, T. (2003). YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up regulated in osteoarthritic chondrocytes. Ann. Rheum. Dis. 62, 995-998.
64. Ku, B.M., Lee, Y.K., Ryu, J., Jeong, J.Y., Choi, J., Eun, K.M., Shin, H.Y., Kim, D.G., Hwang, E.M., Yoo, J.C., et al. (2011). CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int. J. Cancer 128, 1316-1326.
65. Kzhyshkowska, J., Gratchev, A., Martens, J.H., Pervushina, O., Mamidi, S., Johansson, S., Schledzewski, K., Hansen, B., He, X., Tang, J., et al. (2004). Stabilin-1 localizes to endosomes and the trans-Golgi network in human macrophages and interacts with GGA adaptors. J. Leukoc. Biol. 76, 1151-1161.
66. Kzhyshkowska, J., Mamidi, S., Gratchev, A., Kremmer, E., Schmuttermaier, C., Krusell, L., Haus, G., Utikal, J., Schledzewski, K., Scholtze, J., et al. (2006). Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 107, 3221-3228.
67. Kzhyshkowska, J., Gratchev, A., Goerdt, S. (2007). Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark. Insights 2, 128-146.
68. Kzhyshkowska, J., Gratchev, A., Schmuttermaier, C., Brundiers, H., Krusell, L., Mamidi, S., Zhang, J., Workman, G., Sage, E. H., Anderle, C., et al. (2008). Alternatively activated macrophages regulate extracellular levels of the hormone placental lactogen via receptor-mediated uptake and transcytosis. J. Immunol. 180, 3028-3037.
69. Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., Hermoso, M. A. (2014). Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 149185. doi 10.1155/2014/149185.
70. Lasek, W., Zagozdzon, R., Jakobisiak, M. (2014). Interleukin 12: still a promising candidate for tumor immunotherapy Cancer Immunol. Immunother. 63, 419-435.
71. Lee, C.G., Da Silva, C.A., Dela Cruz, C.S., Ahangari, F., Ma, B., Kang, M.J., He, C.H., Takyar, S., Elias, J.A. (2011). Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 73, 479-501.
72. Leivonen, M., Lundin, J., Nordling, S., von Boguslawski, K., Haglund, C. (2004). Prognostic value of syndecan-1 expression in breast cancer. Oncology 67, 11-18.
73. Libreros, S., Iragavarapu-Charyulu, V. (2015). YKL-40/CHI3L1 drives inflammation on the road of tumor progression. J. Leukoc. Biol. 98, 931-936.
74. Libreros, S., Garcia-Areas, R., Shibata, Y., Carrio, R., Torroella-Kouri, M., Iragavarapu-Charyulu, V. (2012). Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model. Int. J. Cancer 131, 377-386.
75. Libreros, S., Garcia-Areas, R., Keating, P., Carrio, R., Iragavarapu-Charyulu, V.L. (2013). Exploring the role of CHI3L1 in "pre-metastatic" lungs of mammary tumor-bearing mice. Front Physiol. 4, 392.
76. Libreros, S., Garcia-Areas, R., Keating, P., Gazaniga, N., Robinson, P., Humbles, A., Iragavarapu-Charyulu, V.L. (2015). Allergen induced pulmonary inflammation enhances mammary tumor growth and metastasis: role of CHI3L1. J Leukoc Biol. 97, 929-940.
77. Low, D., Subramaniam, R., Lin, L., Aomatsu, T., Mizoguchi, A., Ng, A., DeGruttola, A.K., Lee, C.G., Elias, J.A., Andoh, A., et al. (2015). Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9. Oncotarget 6, 36535-36550.
78. Lu, K.V., Jong, K.A., Rajasekaran, A.K., Cloughesy, T.F., Mischel, P.S. (2004). Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest. 84, 8-20.
79. Ma, B., Herzog, E.L., Lee, C.G., Peng, X., Lee, C.M., Chen, X., Rockwell, S., Koo, J.S., Kluger, H., Herbst, R.S., et al. (2015). Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Res. 75, 487-496.
80. Maeda, T., Desouky, J., Friedl, A. (2006). Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 25, 1408-1412.
81. Malik, P., Chaudhry, N., Mittal, R., Mukherjee, T.K. (2015). Role of receptor for advanced glycation end products in the complication and progression of various types of cancers. Biochim. Biophys. Acta 1850, 1898-1904.
82. Malinda, K.M., Ponce, L., Kleinman, H.K., Shackelton, L.M., Millis, A.J. (1999). Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp. Cell Res. 250, 168-173.
83. Martens, J.H., Kzhyshkowska, J., Falkowski-Hansen, M., Schledzewski, K., Gratchev, A., Mansmann, U., Schmuttermaier, C., Dippel, E., Koenen, W., Riedel, F., et al. (2006). Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis. J. Pathol. 208, 574-589.
84. Meng, G., Zhao, Y., Bai, X., Liu, Y., Green, T.J., Luo, M., Zheng, X. (2010). Structure of human stabilin-1 interacting chitinase-like protein (SI-CLP) reveals a saccharide-binding cleft with lower sugar-binding selectivity. J. Biol. Chem. 285, 39898-39904.
85. Miyatake, K., Tsuji, K., Yamaga, M., Yamada, J., Matsukura, Y., Abula, K., Sekiya, I., Muneta, T. (2013). Human YKL39 (chitinase 3-like protein 2), an osteoarthritis-associated gene, enhances proliferation and type II collagen expression in ATDC5 cells. Biochem. Biophys. Res. Commun. 431, 52-57.
86. Mosig, S., Rennert, K., Krause, S., Kzhyshkowska, J., Neunubel, K., Heller, R., Funke, H. (2009). Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14CD16monocytes in detoxification of oxidized LDL. FASEB J 23, 866-874.
87. Nielsen, A.R., Erikstrup, C., Johansen, J.S., Fischer, C.P., Plomgaard, P., Krogh-Madsen, R., Taudorf, S., Lindegaard, B., Pedersen, B.K. (2008). Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 57, 3078-3082.
88. Nishikawa, K.C., Millis, A.J. (2003). gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp. Cell Res. 287, 79-87.
89. Otsuka, K., Matsumoto, H., Niimi, A., Muro, S., Ito, I., Takeda, T., Terada, K., Yamaguchi, M., Matsuoka, H., Jinnai, M., et al. (2012). Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respiration 83, 507-519.
90. Otterdal, K., Janardhanan, J., Astrup, E., Ueland, T., Prakash, J.A., Lekva, T., Abraham, O.C., Thomas, K., Damas, J.K., Mathews, P., et al. (2014). Increased endothelial and macrophage markers are associated with disease severity and mortality in scrub typhus. J. Infect. 69, 462-469.
91. Ozdemir, E., Cicek, T., Kaya, M.O. (2012). Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer. Urol. J. 9, 568-573.
92. Park, J.A., Drazen, J.M., Tschumperlin, D.J. (2010). The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress. J. Biol. Chem. 285, 29817-29825.
93. Pelloski, C.E., Mahajan, A., Maor, M., Chang, E.L., Woo, S., Gilbert, M., Colman, H., Yang, H., Ledoux, A., Blair, H., et al. (2005). YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. 11, 3326-3334.
94. Petersson, M., Bucht, E., Granberg, B., Stark, A. (2006). Effects of arginine-vasopressin and parathyroid hormone-related protein (1-34) on cell proliferation and production of YKL-40 in cultured chondrocytes from patients with rheumatoid arthritis and osteoarthritis. Osteoarthritis Cartilage 14, 652-659.
95. Qian, H., Johansson, S., McCourt, P., Smedsrod, B., Ekblom, M., Johansson, S. (2009). Stabilins are expressed in bone marrow sinusoidal endothelial cells and mediate scavenging and cell adhesive functions. Biochem. Biophys. Res. Commun. 390, 883-886.
96. Qian, B.Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., Kaiser, E.A., Snyder, L.A., Pollard, J.W. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225.
97. Qureshi, A.M., Hannigan, A., Campbell, D., Nixon, C., Wilson, J.B. (2011). Chitinase-like proteins are autoantigens in a model of inflammation-promoted incipient neoplasia. Genes Cancer 2, 74-87.
98. Ranok, A., Wongsantichon, J., Robinson, R.C., Suginta, W. (2015). Structural and thermodynamic insights into chitooligosaccharide binding to human cartilage chitinase 3-like protein 2 (CHI3L2 or YKL-39). J. Biol. Chem. 290, 2617-2629.
99. Rathcke, C.N., Persson, F., Tarnow, L., Rossing, P., Vestergaard, H. (2009). YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 32, 323-328.
100. Renkema, G.H., Boot, R.G., Au, F.L., Donker-Koopman, W.E., Strijland, A., Muijsers, A.O., Hrebicek, M., Aerts, J.M. (1998). Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur. J. Biochem. 251, 504-509.
101. Riabov, V., Gudima, A., Wang, N., Mickley, A., Orekhov, A., Kzhyshkowska, J. (2014). Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 5, 75.
102. Roslind, A., Johansen, J.S., Christensen, I.J., Kiss, K., Balslev, E., Nielsen, D.L., Bentzen, J., Price, P.A., Andersen, E. (2008a). High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int. J. Cancer 122, 857-863.
103. Roslind, A., Knoop, A.S., Jensen, M.B., Johansen, J.S., Nielsen, D.L., Price, P.A., Balslev, E. (2008b). YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res. Treat. 112, 275-285.
104. Saidi, A., Javerzat, S., Bellahcene, A., De Vos, J., Bello, L., Castronovo, V., Deprez, M., Loiseau, H., Bikfalvi, A., Hagedorn, M. (2008). Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int. J. Cancer 122, 2187-2198.
105. Salamon, J., Hoffmann, T., Elies, E., Peldschus, K., Johansen, J.S., Luers, G., Schumacher, U., Wicklein, D. (2014). Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One 9, e95822.
106. Schimpl, M., Rush, C.L., Betou, M., Eggleston, I.M., Recklies, A.D., van Aalten, D.M. (2012). Human YKL-39 is a pseudo-chitinase with retained chitooligosaccharide-binding properties. Biochem. J. 446, 149-157.
107. Schledzewski, K., Falkowski, M., Moldenhauer, G., Metharom, P., Kzhyshkowska, J., Ganss, R., Demory, A., Falkowska-Hansen, B., Kurzen, H., Ugurel, S., et al. (2006). Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1, F4/80, CD11bmacrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J. Pathol. 209, 67-77.
108. Schmidt, H., Johansen, J.S., Gehl, J., Geertsen, P.F., Fode, K., von der Maase, H. (2006a). Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106, 1130-1139.
109. Schmidt, H., Johansen, J.S., Sjoegren, P., Christensen, I.J., Sorensen, B.S., Fode, K., Larsen, J., von der Maase, H. (2006b). Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J. Clin. Oncol. 24, 798-804.
110. Schonhaar, K., Schledzewski, K., Michel, J., Dollt, C., Gkaniatsou, C., Geraud, C., Kzhyshkowska, J., Goerdt, S., Schmieder, A. (2014). Expression of stabilin-1 in M2 macrophages in human granulomatous disease and melanocytic lesions. Int. J. Clin. Exp. Pathol. 7, 1625-1634.
111. Schultz, N.A., Christensen, I.J., Werner, J., Giese, N., Jensen, B.V., Larsen, O., Bjerregaard, J.K., Pfeiffer, P., Calatayud, D., Nielsen, S. E., et al. (2013). Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One 8, e67059.
112. Sengupta, S., Thaci, B., Crawford, A.C., Sampath, P. (2014). Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed. Res. Int. 2014, 952128. doi 10.1155/2014/952128.
113. Shackelton, L.M., Mann, D.M., Millis, A.J. (1995). Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J. Biol. Chem. 270, 13076-13083.
114. Shao, R. (2013). YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol. 4, 122.
115. Shao, R., Hamel, K., Petersen, L., Cao, Q.J., Arenas, R.B., Bigelow, C., Bentley, B., Yan, W. (2009). YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28, 4456-4468.
116. Shao, R., Cao, Q.J., Arenas, R.B., Bigelow, C., Bentley, B., Yan, W. (2011). Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br. J. Cancer 105, 1203-1209.
117. Shao, R., Francescone, R., Ngernyuang, N., Bentley, B., Taylor, S.L., Moral, L., Yan, W. (2014). Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis 35, 373-382.
118. Singh, S.K., Bhardwaj, R., Wilczynska, K.M., Dumur, C.I., Kordula, T. (2011). A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J. Biol. Chem. 286, 39893-39903.
119. Sohn, M.H., Kang, M.J., Matsuura, H., Bhandari, V., Chen, N.Y., Lee, C.G., Elias, J.A. (2010). The chitinase-like proteins breast regression protein-39 and YKL-40 regulate hyperoxia-induced acute lung injury. Am. J. Respir. Crit. Care Med. 182, 918-928.
120. St-Jacques, S., Bleau, G. (1988). Monoclonal antibodies specific for an oviductal component associated with the hamster zona pellucida. J. Reprod. Immunol. 12, 247-261.
121. Steck, E., Breit, S., Breusch, S.J., Axt, M., Richter, W. (2002). Enhanced expression of the human chitinase 3-like 2 gene (YKL-39) but not chitinase 3-like 1 gene (YKL-40) in osteoarthritic cartilage. Biochem. Biophys. Res. Commun. 299, 109-115.
122. Tschirdewahn, S., Reis, H., Niedworok, C., Nyirady, P., Szendroi, A., Schmid, K.W., Shariat, S.F., Kramer, G., vom Dorp, F., Rubben, H., et al. (2014). Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol. Oncol. 32, 663-669.
123. Volck, B., Price, P.A., Johansen, J.S., Sorensen, O., Benfield, T.L., Nielsen, H.J., Calafat, J., Borregaard, N. (1998). YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc. Assoc. Am. Physicians. 110, 351-360.
124. Vom Dorp, F., Tschirdewahn, S., Niedworok, C., Reis, H., Krause, H., Kempkensteffen, C., Busch, J., Kramer, G., Shariat, S.F., Nyirady, P., et al. (2015). Circulating and tissue expression levels of YKL-40 in renal cell cancer. J. Urol. 5347, 04920-04924.
125. Voronov, E., Dotan, S., Krelin, Y., Song, X., Elkabets, M., Carmi, Y., Rider, P., Idan, C., Romzova, M., Kaplanov, I., et al. (2013). Unique versus redundant functions of IL-1a and IL-1b in the tumor microenvironment. Front Immunol. 4, 177.
126. Vos, K., Steenbakkers, P., Miltenburg, A.M., Bos, E., van Den Heuvel, M.W., van Hogezand, R.A., de Vries, R.R., Breedveld, F.C., Boots, A.M. (2000). Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 59, 544-548.
127. Ward, J.M., Yoon, M., Anver, M.R., Haines, D.C., Kudo, G., Gonzalez, F.J., Kimura, S. (2001). Hyalinosis and Ym1/Ym2 gene expression in the stomach and respiratory tract of 129S4/SvJae and wild-type and CYP1A2-null B6, 129 mice. Am. J. Pathol. 158, 323-332.
128. Xiao, W., Meng, G., Zhao, Y., Yuan, H., Li, T., Peng, Y., Zhao, Y., Luo, M., Zhao, W., Li, Z., Zheng, X. (2014). Human secreted protein SI-CLP aggravates the inflammation of rheumatoid arthritis and is a potential macrophage inflammatory regulator. Arthritis Rheumatol. 66, 1141-1152.
129. Xu, Y., Yuan, J., Zhang, Z., Lin, L., Xu, S. (2012). Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis. Mol. Biol. Rep. 39, 8979-8985.
130. Xu, C.H., Yu, L.K., Hao, K.K. (2014). Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 9, e96384.
131. Zhang, J., Gratchev, A., Riabov, V., Mamidi, S., Schmuttermaier, C., Krusell, L., Kremmer, E., Workman, G., Sage, E. H., Jalkanen, S., et al. (2009). A novel GGA-binding site is required for intracellular sorting mediated by stabilin-1. Mol. Cell Biol. 29, 6097-6105.
132. Zheng, X., Xing, S., Liu, X.M., Liu, W., Liu, D., Chi, P.D., Chen, H., Dai, S.Q., Zhong, Q., Zeng, M.S., et al. (2014). Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma. BMC Cancer 14, 490.
133. Zhu, C.B., Chen, L.L., Tian, J.J., Su, L., Wang, C., Gai, Z.T., Du, W.J., Ma, G.L. (2012). Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 19, 817-825.